[
    {
        "trial_id": "NCT06690996",
        "brief_title": "A Study of LY4005130 in Healthy Participants",
        "official_title": "A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single-ascending Dose and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4005130 in Healthy Participants.",
        "lillyAlias": [
            "J5D-MC-FPAB"
        ],
        "brief_summary": "The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it.\n\nPart A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for the multiple-ascending doses (MAD) of the study will either last about 16 weeks with 13 visits or 20 weeks with 12 visits not counting the time for screening.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Healthy"
        ],
        "drugs_list": [
            "LY4005130",
            "LY4005130",
            "Placebo",
            "Placebo"
        ],
        "enrollment": 140,
        "inclusion_criteria": "inclusion criteria: \n\n Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead (electrocardiogram) ECG. If any values are outside the normal range and considered to be significant, for example, elevated white blood cell count, the respective test may be repeated once at the discretion of the investigator without consultation with the sponsor\n If enrolled as Japanese or Chinese, the entry requirements are as follows:\n\n   To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan\n   To qualify as Chinese for the purpose of this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China\n Have a body weight 45 kilogram (kg) or greater and body mass index greater than 18 and less than 32 kilogram per square meter (kg/m\u00b2)",
        "exclusion_criteria": "exclusion criteria: \n\nAre an individual of childbearing potential (IOCBP)\nHave known allergies to LY4005130, related compounds, or any components of the formulation\nHave received a live vaccine within 28 days of screening or intend to do so during the study or within 28 days after the study\n\n  Non-live or inactivated vaccinations are allowed\n  Bacillus Calmette Guerin vaccine must not have been administered within 12 months before screening\nHad a surgical procedure within 12 weeks before screening;\n\n  during the study, or\n  within 28 days after the study\nHave a history of allergy to medications that could be used to treat infusion reactions, or to the drug excipients\nHave a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, significant history of atopy, or a history of severe posttreatment hypersensitivity reactions. These reactions include, but are not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis\nHave a diagnosis or history of malignant disease within 5 years prior to screening, with the following exceptions\n\n  Basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or\n  Cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to screening\nHave had breast cancer within the past 10 years\nHave a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant\nHave a current or recent acute, active infection",
        "keywords": []
    },
    {
        "trial_id": "NCT06153355",
        "brief_title": "A First-In-Human Study of LY3839840 in Healthy Participants",
        "official_title": "Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3839840 Following Oral Dosing in Healthy Participants",
        "lillyAlias": [
            "J4U-MC-KTAA"
        ],
        "brief_summary": "The main purpose of this first-in-human study to investigate the safety of LY3839840 in single and multiple doses, and how it's processed in the body when given in different amounts.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Healthy"
        ],
        "drugs_list": [
            "LY3839840",
            "Placebo",
            "Midazolam"
        ],
        "enrollment": 178,
        "inclusion_criteria": "inclusion criteria: \n\nHealthy men and women. Women may only be included if they are of nonchildbearing potential\n\nFor Part C:\n\n\u2022 Part C of the study includes Chinese participants only. To qualify, the participants must be considered as native Chinese, defined as all the participant's biological grandparents being of Chinese origin\n\nFor Part D:\n\n Part D of the study includes Japanese participants only. To qualify, the participants must be first-generation Japanese, defined as the participant's biological parents, and all the participant's biological grandparents, being of exclusive Japanese descent, and being born in Japan\n Participants who are healthy as determined through medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead (electrocardiogram ECG)\n Have a body mass index (BMI) of greater than or equal to 18 to less than or equal to 35 kilograms per square meter (kg/m\u00b2). For Parts C and D: BMI greater than or equal to 18 to less than or equal to 29 kilograms per square meter (kg/m\u00b2)\n Participants who have laboratory tests within the normal reference range for the population or CRU or have results with acceptable deviations that are judged by the investigator not to be clinically significant\n Have venous access sufficient to allow for blood sampling",
        "exclusion_criteria": "exclusion criteria: \n\nHave known allergies to LY3839840, related compounds, or any components of the formulation\nHave a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy\nHave a significant history of or current rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome, hyperthyroidism, hyperaldosteronism), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational medicinal product; or of interfering with the interpretation of data\nHave had any significant infections within 3 months prior to the screening visit, or develop any of these infections before the randomization visit.\nHave received \u22651 live vaccine within 28 days of screening, or intend to during the study, or \u226428 days after the study\nHad any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or intend to during the study, or \u226428 days after the study\nHad any malignancy within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma with no evidence of recurrence or metastatic disease within the past 3 years\nHave a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant\nHave used, or intend to use, prescription or nonprescription medication within 14 days prior to dosing (or 5 half-lives - whichever is longer)\nAre currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study\nHave participated in a clinical study involving an investigational product within the last 30 days of the final drug administration (or 5 half-lives - whichever is longer)\nShow evidence of active or latent TB\nAre females who are lactating or have a positive pregnancy test at screening or Day -1\nBlood donation of \u2265450 mL, or participation in a clinical study that required a blood volume of \u2265400 mL since the last study visit within the past 120 days",
        "keywords": []
    },
    {
        "trial_id": "NCT04088396",
        "brief_title": "A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "official_title": "Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.",
        "lillyAlias": [
            "I4V-MC-JAHU"
        ],
        "brief_summary": "The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Systemic Juvenile Idiopathic Arthritis"
        ],
        "drugs_list": [
            "Baricitinib",
            "Tocilizumab"
        ],
        "enrollment": 58,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years\n Participants must have at least 2 active joints at screening and baseline\n Cohort 1 (IL-6 inhibitor therapy naive): Participants who are at least 1 year and less than 18 years of age, except in countries that restrict use of tocilizumab in participants less than 2 years of age\n Cohort 2 (open-label baricitinib): Participants who are at least 1 year and less than 18 years of age",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis\nParticipants must not have persistent oligoarticular arthritis as defined by the ILAR criteria\nParticipants must not have a history or presence of any autoimmune inflammatory condition other than JIA\nParticipants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis\nParticipants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study\nParticipants must not have biologic features of Macrophage Activation Syndrome (MAS) over the past 12 weeks\nParticipants must not have a current or recent (\\<4 weeks prior to baseline) clinically serious infection\nParticipants must not have a positive test for hepatitis B virus\nParticipants must not have evidence of active tuberculosis (TB) or untreated latent TB",
        "keywords": [
            "Systemic",
            "Fever",
            "Flare",
            "sJIA",
            "JIA"
        ]
    },
    {
        "trial_id": "NCT05074420",
        "brief_title": "A Study of Baricitinib (LY3009104) in Children With COVID-19",
        "official_title": "A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19",
        "lillyAlias": [
            "I4V-MC-KHAB"
        ],
        "brief_summary": "The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Covid19",
            "Corona Virus Infection"
        ],
        "drugs_list": [
            "Baricitinib"
        ],
        "enrollment": 24,
        "inclusion_criteria": "inclusion criteria: \n\n Hospitalized with coronavirus (SARS-CoV-2) infection.\n Male or female participants from 1 to \\<18 years of age.\n Requires supplemental oxygen and have chest imaging findings to confirm respiratory disease due to COVID-19 within 72 hours of study entry and enrollment.\n Supplemental oxygen including but not limited to: nasal cannula, mask, high flow devices, CPAP/BiPAP, invasive mechanical ventilation as well as ECMO.",
        "exclusion_criteria": "exclusion criteria: \n\nAre receiving biologic treatments (such as Tumor Necrosis Factor \\[TNF\\] inhibitors, interleukin inhibitors, T-cell or B-cell targeted therapies, interferon, or Janus kinase (JAK) inhibitors); or are receiving other immunosuppressants such that, in the opinion of the investigator, participating in the study would put the participant at an unacceptable risk of immunosuppression.\n\nNote: A washout period is required prior to screening.\n\nAre receiving strong inhibitors of Organic Anion Transporter 3 (OAT3) (such as probenecid) that cannot be discontinued at study entry.\nHave diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required).\nSuspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product.\nHave received any live vaccine within 4 weeks before screening, or intend to receive a live vaccine during the study. Note: Use of non-live (inactivated) vaccinations are allowed for all participants.\nRequire invasive mechanical ventilation, including extracorporeal membrane oxygenation (ECMO) at study entry.\nCurrent diagnosis of active malignancy that, in the opinion of the investigator, could constitute a risk when taking investigational product.\nHave a history of venous thromboembolism (VTE) (deep vein thrombosis \\[DVT\\] and/or pulmonary embolism \\[PE\\]) or considered high risk of VTE (DVT/PE).\nAnticipated discharge from the hospital, or transfer to another hospital (or another unit), which is not a study site within 72 hours after study entry.\nHave neutropenia (absolute neutrophil count \\<1000 cells/microliters).\nHave lymphopenia (absolute lymphocyte count \\<200 cells/microliters).\nHave alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>5 times AAULN.\nEstimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease \\[MDRD\\]) \\<40 milliliter/minute/1.73 meters squared.\nHave a known hypersensitivity to baricitinib or any of its excipients.\nAre currently enrolled in any other clinical study involving an investigation product or any other type of medical research judged not to be scientifically or medically compatible with this study. Note: The participant should not be enrolled (started) in another clinical trial for the treatment of COVID-19 or SARS CoV-2 through Day 28.\nAre pregnant, or intend to become pregnant or breastfeed during the study.\nAre, in the opinion of the investigator or sponsor, at risk of immunosuppression or otherwise unsuitable for inclusion in the study.\nAre using or will use extracorporeal blood purification (EBP) device to remove proinflammatory cytokines from the blood such as a cytokine absorption or filtering device, for example, CytoSorb\u00ae.\nAre, in the opinion of the investigator, unlikely to survive for at least 48 hours after screening.",
        "keywords": [
            "coronavirus"
        ]
    },
    {
        "trial_id": "NCT03773965",
        "brief_title": "A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",
        "official_title": "A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)",
        "lillyAlias": [
            "I4V-MC-JAHX"
        ],
        "brief_summary": "The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Juvenile Idiopathic Arthritis"
        ],
        "drugs_list": [
            "Baricitinib"
        ],
        "enrollment": 190,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have completed a previous study of baricitinib for the treatment of JIA.",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have had a permanent discontinuation of baricitinib in the prior study.\nParticipants must have not developed an allergy to baricitinib.",
        "keywords": [
            "Polyarticular JIA",
            "Oligoarthritis",
            "Juvenile psoriatic arthritis (JPsA)",
            "Enthesitis-related juvenile idiopathic arthritis (ERA)",
            "Systemic JIA with and without systemic features"
        ]
    },
    {
        "trial_id": "NCT06395012",
        "brief_title": "A First-In-Human Study of LY3985297 in Healthy Participants",
        "official_title": "A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3985297 in Healthy Participants",
        "lillyAlias": [
            "J4S-MC-KSAA"
        ],
        "brief_summary": "The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it.\n\nThe study is conducted in two parts (part A and B), each part has a separate treatment cohort.\n\nThe study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Healthy"
        ],
        "drugs_list": [
            "LY3985297",
            "Placebo"
        ],
        "enrollment": 153,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must be overtly healthy, as determined by medical evaluation.\n Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m\u00b2), inclusive, and a minimum body weight of 45.0 kg.\n Participants must be assigned male or female at birth and not of childbearing potential.\n Have normal blood pressure, pulse rate, electrocardiogram (ECG), clinical laboratory test results that are acceptable for the study.\n Have venous access sufficient to allow for blood sampling.\n\nFor Part A Cohorts 5, 6, and 7:\n\n Participants must be first-generation Japanese only, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan. Or\n Participants must be first-generation Chinese only, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Chinese descent and born in China.",
        "exclusion_criteria": "exclusion criteria: \n\nHave a current or recent acute, active infection. For at least 30 days before screening and up to the randomization visit (Day 1).\nHad any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening or intend to during the study.\nHave a history of multiple or severe allergies, or an anaphylactic reaction, to prescription or nonprescription drugs or food.\nShow evidence of active or latent tuberculosis (TB).\nHave one of the following infections: hepatitis B, C virus or human immunodeficiency virus (HIV).",
        "keywords": []
    },
    {
        "trial_id": "NCT06859294",
        "brief_title": "A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis",
        "official_title": "A Phase 2a, Single-Arm Study to Investigate the Efficacy and Safety of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis",
        "lillyAlias": [
            "J3K-MC-KIAC"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).\n\nStudy participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Rheumatoid Arthritis"
        ],
        "drugs_list": [
            "LY3541860"
        ],
        "enrollment": 40,
        "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria.\n Have moderately to severely active RA, at screening (Visit 1) and baseline (Visit 2), defined by the presence of\n\n   \u22656 swollen joints based on 66 joint count (and \u22654 swollen joints on 28 joint count), and\n   \u22656 tender joints based on 68 joint count (and \u22654 tender joints on 28 joint count).\n Have active synovitis in \u22651 joint, in hands or wrists, of the investigator choosing at screening, having an MRI synovitis RAMRIS score of \u22652 as determined from the central reading of the images.",
        "exclusion_criteria": "exclusion criteria: \n\nHave a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of\n\n  basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or\n  cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline.\nHave estimated glomerular filtration rate (eGFR) of \\<45 milliliter per minute (mL/minute) from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.\nHave a current or recent active infection.\nHave presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to\n\n  poorly controlled diabetes or hypertension\n  chronic kidney disease Stage 3a or b, 4, or 5\n  symptomatic heart failure according to New York Heart Association Class 2, 3, or 4\n  myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before baseline\n  severe chronic pulmonary disease, for example, requiring oxygen therapy major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to\n  systemic lupus erythematosus\n  psoriatic arthritis\n  axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis\n  reactive arthritis\n  gout\n  scleroderma\n  polymyositis\n  dermatomyositis\n  active fibromyalgia, or\n  multiple sclerosis\nHave received any prior B-cell targeted therapy (for example, anti-CD19 antibodies or anti-CD20 antibodies, such as rituximab).\nReceived corticosteroids, opioids, conventional disease-modifying antirheumatic drug (cDMARD), with changes in dose or have received Janus kinase (JAK) inhibitors within 28 days prior to the screening MRI or plan on receiving these drugs during the study.",
        "keywords": []
    },
    {
        "trial_id": "NCT06280716",
        "brief_title": "A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis",
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Trial to Investigate the Efficacy and Safety of Lebrikizumab When Used With/Without Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis",
        "lillyAlias": [
            "J2T-MC-KGBW"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Atopic Dermatitis"
        ],
        "drugs_list": [
            "Placebo",
            "Lebrikizumab",
            "Topical Corticosteroid"
        ],
        "enrollment": 430,
        "inclusion_criteria": "inclusion criteria: \n\n Have chronic AD that has been present for \u22651 year before the screening period or have chronic eczema and meet the AAD criteria.\n Have moderate-to-severe AD, including all of the following at the baseline: EASI score \u226516, IGA score \u22653 (scale of 0 to 4), \u226510% BSA of AD involvement.\n Have a documented history provided by a physician and/or investigator of inadequate response to existing topical medications within 6 months preceding screening as defined by at least 1 of the following:\n\n  1. Inability to achieve good disease control, defined as mild disease or better after use of at least a medium-potency TCS for at least 4 weeks, or for the maximum duration recommended by the product prescribing information, whichever is shorter. TCS may be used with or without TCIs and/or topical Janus kinase (JAK) inhibitors.\n  2. Participants who failed systemic therapies intended to treat AD within 6 months preceding screening, such as cyclosporine, MTX, azathioprine, and MMF, will also be considered as surrogates for having inadequate response to topical therapy.\n Adolescents body weight must be \u226540 kg at baseline.\n Males may participate in this trial and comply with specific local government study requirements. Females of childbearing potential and females not of childbearing potential may participate in this trial.",
        "exclusion_criteria": "exclusion criteria: \n\nHave received a dose of lebrikizumab in any prior lebrikizumab clinical study.\nHave a history of anaphylaxis or uncontrolled chronic disease that might require bursts of oral corticosteroids.\nHave a current or recent acute, active infection. For at least 30 days before screening and up to the randomization, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment.\nHave had Serious, Opportunistic, Chronic and Recurring infection within 3 months prior to the screening or develops any of these infections before the randomization.\nHave active tuberculosis (TB) or latent tuberculosis infection (LTBI) that has not been treated with a complete course of appropriate therapy or such treatment is underway.\nHave a current infection with HBV, HCV, human immunodeficiency virus (HIV) infection.\nHave presence of skin comorbidities that may interfere with study assessments.\nHave a diagnosis or history of malignant disease within 5 years before screening, with the following exceptions:\n\n  1. basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, and\n  2. cervical carcinoma in situ, with no evidence of recurrence within 5 years before screening visit.\nPregnant or breastfeeding women or women planning to become pregnant or breastfeed during the study.",
        "keywords": []
    },
    {
        "trial_id": "NCT05723198",
        "brief_title": "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata",
        "official_title": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata",
        "lillyAlias": [
            "I4V-MC-JAIO"
        ],
        "brief_summary": "The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.\n\nThe study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Areata Alopecia",
            "Alopecia",
            "Hypotrichosis",
            "Hair Diseases",
            "Skin Diseases",
            "Pathological Conditions, Anatomical"
        ],
        "drugs_list": [
            "Baricitinib",
            "Placebo"
        ],
        "enrollment": 595,
        "inclusion_criteria": "inclusion criteria: \n\n Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).\n Have severe areata alopecia (AA) for at least 1 year\n Diagnosis for at least 1 year\n Current AA episode of at least 6 months' duration\n SALT score \u226550% at screening and baseline\n History of trial and failure with at least 1 available treatment (topical or other) for AA\n History of psychological counseling related to AA\n Current episode of severe AA of less than 8 years.\n\n   Note: Participants who have severe AA for \u22658 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.",
        "exclusion_criteria": "exclusion criteria: \n\nPrimarily \"diffuse\" type of AA (characterized by diffuse hair shedding).\nAre currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on AA.\nAre largely or wholly incapacitated permitting little or no self-care, such as being bedridden\nHave uncontrolled arterial hypertension\nHave had major surgery within 8 weeks prior to screening or will require major surgery during the study\nHave a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking IP or interfere with the interpretation of data.\nHave a positive test for hepatitis B virus (HBV) infection\nHave hepatitis C virus (HCV) infection (positive for anti hepatitis C antibody with confirmed presence of HCV ribonucleic acid \\[RNA\\]).\nHave evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies.",
        "keywords": []
    },
    {
        "trial_id": "NCT05784246",
        "brief_title": "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis",
        "official_title": "A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis",
        "lillyAlias": [
            "I6T-MC-AMBA"
        ],
        "brief_summary": "The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Ulcerative Colitis"
        ],
        "drugs_list": [
            "Mirikizumab IV",
            "Mirikizumab SC"
        ],
        "enrollment": 60,
        "inclusion_criteria": "inclusion criteria: \n\n Males or females weighing \u226510 kg and \u22652 and \\<18 years old at the time of consent for screening.\n Have moderate to severe UC.\n Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.\n Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.",
        "exclusion_criteria": "exclusion criteria: \n\nHave Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis or primary sclerosing cholangitis.\nHave immune deficiency syndrome.\nPrevious bowel resection or intestinal surgery.\nEvidence of toxic megacolon.\nHistory or current evidence of cancer of the gastrointestinal tract.",
        "keywords": []
    },
    {
        "trial_id": "NCT05509777",
        "brief_title": "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease",
        "official_title": "A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease",
        "lillyAlias": [
            "I6T-MC-AMAY",
            "I6T-MC-PIBD"
        ],
        "brief_summary": "Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.\n\nStudy periods for the intervention-specific appendix (ISA) will be as follows:\n\n* A 12-week induction period\n* A maintenance period from Week 12 to Week 52, and\n* A safety follow-up period up to 16 weeks.\n\nThe study will last about 74 weeks and may include up to 19 visits.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Crohn's Disease"
        ],
        "drugs_list": [
            "Mirikizumab"
        ],
        "enrollment": 90,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have a diagnosis of CD or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.\n Participants have moderately to severely active CD (as defined by a baseline PCDAI score \u226530).\n Participants must have endoscopy with evidence of active CD defined as SES-CD score \u22656 (or \u22654 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0.\n Participants must have a documented history of inadequate response, loss of response or intolerance to at least one medication used to treat CD, which may include immunomodulators, oral or IV corticosteroids, a biologic therapy or a JAK inhibitor.",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestations that might be anticipated to require surgery.\nParticipants must not have an abscess.\nParticipants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline.",
        "keywords": [
            "Inflammatory Bowel Disease"
        ]
    },
    {
        "trial_id": "NCT06292013",
        "brief_title": "A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)",
        "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a)",
        "lillyAlias": [
            "J3L-MC-EZEF"
        ],
        "brief_summary": "The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Atherosclerotic Cardiovascular Disease (ASCVD)",
            "Elevated Lp(a)"
        ],
        "drugs_list": [
            "Lepodisiran Sodium",
            "Placebo"
        ],
        "enrollment": 12500,
        "inclusion_criteria": "inclusion criteria: \n\n Have Lipoprotein(a) \\[Lp(a)\\] \u2265175 nanomoles per liter (nmol/L).\n Meet criteria of either 2a or 2b:\n\n  2a: Individuals 18 years of age or older with established atherosclerotic cardiovascular disease (ASCVD) with an event or revascularization.\n\n  2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without history of event or revascularization; known familial hypercholesteremia; or a combination of high-risk factors.",
        "exclusion_criteria": "exclusion criteria: \n\nHave had a major cardiovascular event or surgery, such as myocardial infarction (MI), stroke or coronary or peripheral revascularization, \\< 60 days before screening\nHave uncontrolled hypertension\nHave New York Heart Association class IV heart failure.\nHave lipoprotein apheresis within 90 days of screening, or planned lipoprotein apheresis during the study.\nHave severe renal failure, defined as\n\n  Estimated glomerular rate (eGFR) \\<15 milliliters per minute per 1.73 meters squared (mL/min/1.73m2) at screening Visit 1, or ongoing dialysis.\nHave a diagnosis of active nephrotic syndrome, or urine albumin-creatinine ratio (UACR) of \u22655000 mg/g at screening Visit 1.\nHave acute or chronic hepatitis, known cirrhosis, signs and symptoms of any other liver disease other than metabolic-associated steatotic liver disease, or exclusionary laboratory results as determined by the central laboratory during screening.",
        "keywords": [
            "ASCVD",
            "LY3819469",
            "lepodisiran"
        ]
    },
    {
        "trial_id": "NCT06148272",
        "brief_title": "A Study of LY3971297 in Healthy Participants",
        "official_title": "A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate",
        "lillyAlias": [
            "J4O-MC-EZHA"
        ],
        "brief_summary": "The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Healthy",
            "Obesity",
            "Hypertension"
        ],
        "drugs_list": [
            "LY3971297",
            "Placebo",
            "LY3971297 IV"
        ],
        "enrollment": 225,
        "inclusion_criteria": "inclusion criteria: \n\n For Parts A, B, C, E, and F: Overtly healthy males or females as determined by medical history and physical examination\n For Parts A, B, C, E, and F: Have a screening body mass index (BMI) in the range of 18.5 to 35 kilogram per square meter (kg/m\u00b2), inclusive, with no significant weight gain or loss in the past 3 months prior to screening\n For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China\n For Part D, participants must have a stable dose of medications within the past 3 months prior to screening\n For Part D, obesity BMI in the range of 30 to 40 kg/m\u00b2, inclusive, with a waist circumference of at least 102 centimeter (cm) for men and at least 89 cm for women for participants of US sites only. For participants of Singaporean, South Asian, Japanese, and/or Chinese Origin at sites outside the US, the BMI range is 27 to 40 kg/m2 and the waist circumference is at least 90 cm for men and at least 80 cm for women\n For Part E, to qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan\n Male participants must agree to adhere to contraception restrictions and female participants must be women not of childbearing potential\n For Part G, have a screening BMI in the range of 18.5 to 40 kg/m\u00b2, inclusive, with no significant weight gain or loss in the past 3 months prior to screening\n For Part G, participants have a decreased estimated glomerular filtration rate (eGFR)\n For Parts D and G, participants are allowed to have stable background treatment for hypertension, type 2 diabetes mellitus (on oral drug therapy and/or long-acting insulin), dyslipidemia (on statin therapy) and/or hypothyroidism as determined by the investigator\n For Part G, Participants should be on a stable dose of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker",
        "exclusion_criteria": "exclusion criteria: \n\nHave a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders\nHave known or ongoing psychiatric disorders that, in the opinion of the investigator, increases the risks associated with study participation\nHave blood pressure and/or pulse rate constituting a risk as determined by the investigator\nHave a systolic blood pressure (BP) of less than 100 millimeters of mercury (mmHg)\nDiagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of equal to or greater than 20 mmHg or a decrease in diastolic blood pressure of equal to or greater than 10 mmHg when compared with BP from the supine position\nFor US sites: have donated blood of more than 500 mL within the previous 3 months of screening or intend to donate blood during the course of the study\nFor Singapore sites: Have donated blood of more than 450 mL or more in the past 3 months or provided any blood donation within the past 1 month before screening\nConsume more than 10 cigarettes per day (or the equivalent) or are unable or unwilling to abstain from nicotine\nHave alcohol intake that exceeds recommended alcohol consumption limits per local regulation or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge\nFor Part D, has concurrent use or anticipated use of phosphodiesterase 5 inhibitor such as vardenafil, tadalafil, and sildenafil, soluble guanylyl cyclase activators (such as riociguat and vericiguat)\nFor Parts D and G, has concurrent or anticipated use of long-acting nitrates or nitric oxide (NO) donors\nFor Part D, has current use of more than 3 mechanism of actions for treatment of hypertension\nFor Part G, has previous or current diagnosis of primary glomerulopathy, vasculitic renal disease, prior dialysis or unstable rapidly progressing renal disease, autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis, or anti-neutrophil cytoplasm antibody-associated vasculitis",
        "keywords": []
    },
    {
        "trial_id": "NCT05395481",
        "brief_title": "A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",
        "official_title": "A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype",
        "lillyAlias": [
            "J3W-MC-GZOA"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Metabolic Dysfunction-Associated Steatohepatitis (MASH)",
            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)"
        ],
        "drugs_list": [
            "LY3849891",
            "Placebo"
        ],
        "enrollment": 176,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have a body mass index (BMI) within the range greater than or equal to (\u2265) 25 and less than (\\<) 50 kilogram per square meter (kg/m\u00b2) inclusive\n Participants must have liver fat content \u226510% in Part A and \u22658% for Part B as determined by MRI-PDFF\n Participants must be carriers of the PNPLA3 I148M allele\n Participants with or without type 2 diabetes mellitus (T2DM)\n\n  o For participants with T2DM, hemoglobin A1c (HbA1c) \\<8% in Part A and \\<9% in Part B\n Male participants agree to use an effective method of contraception for the duration of the study and for 90 days after the last dose of study intervention\n Women not of childbearing potential may participate and include those who are: infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or those who are postmenopausal",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have known or suspected alcohol abuse (\\>14 units/week for women and \\>21 units/week for men) or active substance abuse\nParticipants must not have evidence of cirrhosis or other forms of liver disease\nParticipants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months\nParticipants must not have active cancer within the last 5 years\nParticipants must not have uncontrolled high blood pressure\nParticipants must not have renal impairment with estimated glomerular filtration rate (eGFR) \\<60 milliliter per minute per 1.73 square meter (ml/min/1.73m\u00b2)\nParticipants must not have a diagnosis of type 1 diabetes\nParticipants must not have a contraindication to MRI examinations, such as persons with cardiac pacemaker and implants made out of metal (for example, cochlear implant, nerve stimulators, magnetic vascular clips, and metallic heart valve) or other contraindications for MRI",
        "keywords": [
            "Hepatic fibrosis",
            "Biomarkers",
            "Magnetic resonance imaging",
            "Pharmacokinetics",
            "Liver fat"
        ]
    },
    {
        "trial_id": "NCT05508789",
        "brief_title": "A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)",
        "official_title": "Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease",
        "lillyAlias": [
            "I5T-MC-AACO"
        ],
        "brief_summary": "The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Alzheimer Disease",
            "Dementia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Tauopathies",
            "Neurodegenerative Diseases",
            "Neurocognitive Disorders",
            "Mental Disorders"
        ],
        "drugs_list": [
            "Donanemab",
            "Placebo"
        ],
        "enrollment": 1500,
        "inclusion_criteria": "inclusion criteria: \n\n Gradual and progressive change in memory function reported by the participant or informant for \u22656 months\n A MMSE score of 20 to 28 (inclusive) at Day 601 or 1.\n Meet flortaucipir F18 scan (central read) criteria\n Meet florbetapir F18 scan (central read) criteria\n Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to the study or be available by telephone at designated times.\n A second study partner may serve as backup. The study partner(s) is/are required to accompany the participant for signing consent. The study partner must be present on all days the cognitive and functional scales are administered.\n If a participant has a second study partner, it is preferred that 1 study partner be primarily responsible for the CDR and the ADCS-ADL assessments.\n Days requiring the following assessments and scales must have a study partner available by telephone if not accompanying participant for the following assessments\n\n   AEs and concomitant medications\n   CDR, and\n   ADCS-ADL\n Stable concomitant symptomatic AD medications and other medications that may impact cognition for at least approximately 30 days prior to randomization.",
        "exclusion_criteria": "exclusion criteria: \n\nHas significant neurological disease affect the central nervous system other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of \\<24 months.\nHistory of cancer within the last 5 years, except of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with low risk of recurrence or spread.\nContraindication to MRI or PET scans",
        "keywords": [
            "Alzheimer's",
            "Dementia",
            "Cognitive Impairment",
            "Amyloid Plaque"
        ]
    },
    {
        "trial_id": "NCT04844606",
        "brief_title": "A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)",
        "official_title": "A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease",
        "lillyAlias": [
            "I6T-MC-AMAZ"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Ulcerative Colitis",
            "Ulcerative Colitis Chronic",
            "Inflammatory Bowel Diseases",
            "Crohn's Disease"
        ],
        "drugs_list": [
            "Mirikizumab",
            "Mirikizumab"
        ],
        "enrollment": 150,
        "inclusion_criteria": "inclusion criteria: \n\n Participants from originating studies (I6T-MC-AMBA \\[NCT05784246\\], I6T-MC-AMBU \\[NCT04004611\\], I6T-MC-AMAM \\[NCT03926130\\]) , I6T-MC-AMAY \\[NCT05509777\\]) who would, in the opinion of the investigator, derive clinical benefit from further treatment with mirikizumab\n Participants from prior studies who have completed assessments and procedures at last visit of originating study and remain on study drug treatment.\n Female participants must agree to contraception requirements.",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have developed a serious adverse event (SAE) or Adverse Event (AE) in originating study or developed other condition before first visit of Study AMAZ that continued treatment with mirikizumab would present an unreasonable risk for the participant.\nParticipants must not have had permanently or temporarily stopped study drug in the originating study, such that restarting mirikizumab would pose an unacceptable risk for the participant in Study AMAZ.\nParticipants must not have an unstable or uncontrolled illness that would potentially affect participant safety.\nParticipants must not be enrolled in the study if, for any reason, being in the study would compromise the participant's safety or confound data interpretation.\nParticipants must not have adenomatous polyps that have not been removed.\nParticipants must not be pregnant or breastfeeding.",
        "keywords": [
            "Pediatric Ulcerative Colitis",
            "Pediatric Crohn's Disease",
            "Pediatric UC",
            "Pediatric CD"
        ]
    },
    {
        "trial_id": "NCT06553872",
        "brief_title": "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL",
        "official_title": "A Phase 2, Open-Label, Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
        "lillyAlias": [
            "J2N-US-I010"
        ],
        "brief_summary": "This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Mantle Cell Lymphoma"
        ],
        "drugs_list": [
            "Pirtobrutinib",
            "Brexucabtagene Autoleucel"
        ],
        "enrollment": 60,
        "inclusion_criteria": "inclusion criteria: \n\n Patients with a histologically confirmed diagnosis of mantle cell lymphoma (MCL) will be eligible.\n Adult males or females who are 18 years of age or older at time of signing informed consent.\n Must have ability to comprehend and the willingness to sign written informed consent for study participation.\n Eligible to receive CAR T-cell therapy (Brexucabtagene autoleucel) for MCL by the standard of care label, which states: \"TECARTUS or Brexucabtagene autoleucel is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL)\"\n ECOG performance status 0 to 2.\n Patients are required to have the following washout periods prior to leukapheresis. In addition, prior treatment-related AEs must have recovered to Grade \u2264 1 with the exception of alopecia and Grade 2 peripheral neuropathy.\n\n   Targeted agents (i.e. BTK inhibitors), investigational agents, therapeutic monoclonal antibodies or cytotoxic chemotherapy: 5 half-lives or 2 weeks, whichever is shorter\n   Antibody-drug conjugates (ADC): 10 weeks\n   Radiation therapy: Broad field radiation (\u2265 30% of the bone marrow or whole brain radiotherapy): 14 days. Palliative limited field radiation: 7 days. Note: In the case of known central nervous system (CNS) involvement by systemic lymphoma: Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.\n   Bendamustine or other purine analogues: 3 months.\n   Corticosteroids: 5 days\n The effects of Pirtobrutinib on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation as outlined in criteria below:\n\n   Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through safety follow up and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants in their understanding confirmed.\n   Willingness of women of reproductive potential and their partners to observe highly effective birth control methods for the duration of treatment and for 1 month following the last dose of study treatment (see Section 4.3 and Section 4.4 for further details)\n   Women of childbearing potential must have a negative serum pregnancy test at screening and before the first dose of pirtobrutinib and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.\n   Women of non-childbearing potential (i.e. surgically sterile with a hysterectomy and/or bilateral oophorectomy OR \\>= 12 months of amenorrhea) are eligible.\n Patients must meet the following laboratory parameters at screening:\n\n   Hematology (criteria the same regardless of bone marrow involvement; must be independent of transfusions and G-CSF support within 7 days of assessment)\n\n     Platelets \\>= 50 x 10\\^9/L\n     Hemoglobin \\>= 8g/dL\n     Absolute Neutrophil Count \\>=1.0 x 10\\^9/L\n   Hepatic\n\n     ALT \\< 2.5 x ULN for age, \\<5 x ULN in the presence of liver metastases\n     AST \\< 2.5 x ULN for age, \\<5 x ULN in the presence of liver metastases\n     Total bilirubin \\< 1.5 x ULN or \\<3 x ULN in the presence of documented Gilbert's syndrome unconjugated hyperbilirubinemia)\n   Renal Creatinine clearance \\>= 30 mL/minute based on Cockcroft-Gault formula.\n   Cardiopulmonary Cardiac LVEF \\>=40% confirmed by ECHO/multigated analysis\n   Adequate pulmonary function \\<= Grade 2 dyspnea and \\<= Grade 2 hypoxia per CTCAE v5.0.\n   Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x ULN.",
        "exclusion_criteria": "exclusion criteria: \n\nPatients who have previously received treatment with pirtobrutinib for \\>2 months prior to study enrollment are ineligible. Patients who are relapsed or refractory and then received less than 2 months of pirtobrutinib as \"holding therapy\" while awaiting CAR T-cell therapy evaluation, and who did not demonstrate disease progression while on pirtobrutinib holding therapy, are eligible.\nPatients who have previously discontinued pirtobrutinib due to disease progression, intolerance, or toxicity.\nPatients who are currently receiving or who have received any investigational study agent \u22644 weeks prior to screening visit are ineligible.\nPrior treatment with chimeric antigen receptor (CAR) T-cell therapy.\nParticipants with clinically significant or uncontrolled cardiac disease, including unstable angina or acute coronary syndrome within the past 2 months prior to randomization, history of myocardial infarction within 3 months prior to randomization, documented LVEF by any method of \u2264 40% in the 12 months prior to randomization, or \u2265 Grade 3 NYHA functional classification system of heart failure.\nUncontrolled or symptomatic arrhythmias, including prolongation of the QT interval corrected for heart rate (QTcF) \\> 470 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT/(RR0.33). Correction of suspected drug induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation. Correction for underlying bundle branch block (BBB) allowed. Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker\nEvidence of active uncontrolled/untreated infection (viral, bacterial, fungal, opportunistic) of any origin.\nParticipants with active immunologic or inflammatory/autoimmune disease affecting the CNS, and unrelated to their disease under study or previous treatment.\nPatients with active CNS involvement of Mantle Cell Lymphoma. A history of CNS Mantle Cell Lymphoma is allowed, as long as it has cleared, and the patient is able to comply with study procedures. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible with documented Sponsor approval.\nKnown positive Human immunodeficiency virus (HIV) status. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment.\nHepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before randomization. Patients who are HBV DNA PCR positive will be excluded. Patients who are HBV DNA PCR negative with positive anti-HBc require prophylaxis against Hepatitis B reactivation (see Section 6.4 \"General Guidance for Hepatic Monitoring\").\nHepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded.\nKnown active cytomegalovirus (CMV) infection. Unknown or negative status are eligible.\nParticipants who require the concurrent use of chronic systemic steroids or immunosuppressant medications. Steroids should not be given within 5 days prior to leukapheresis. Concomitant bridging steroids (section 6.6) are allowed after leukapheresis.\nKnown hypersensitivity or severe reaction to pirtobrutinib, similar compounds, or excipients.\nParticipants who have not recovered from adverse events (AEs) due to prior anticancer therapy (i.e., have residual toxicities \\> Grade 1), with the exception of stable Grade 2 peripheral neuropathy and/or any grade alopecia.\nPregnant or nursing (breast-feeding) women are excluded from this study because there is an unknown but potential risk to using pirtobrutinib in pregnant or nursing women. Patients are excluded if they are pregnant or plan to become pregnant during the study or within 1 year of the last dose of study treatment. Patients are also excluded if they are lactating or plan to breastfeed during the study or within 1 week of the last dose of study treatment. Please see Section 4.3 and Section 4.4 for General Guidance for Women of Child Bearing Potential and/or Use of Contraceptive Methods.\nAny condition that would, in the investigator's judgement, interfere with full participation in the study, including administration of pirtobrutinib and attending required study visits (if outpatient); pose a significant risk to the participant; or interfere with interpretation of study data.\nInability of the participant to swallow and retain oral medication. Or, if there is clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug.\nPatients who experienced a major bleeding event or grade \u2265 3 arrhythmia on prior treatment with a BTK inhibitor. NOTE: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2g per deciliter; or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)\nMajor surgery within 4 weeks prior to enrollment.\nHistory of a previously diagnosed hereditary bleeding disorder.\nPatients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.\nActive second malignancy unless in remission and with life expectancy \\> 2 years.\nVaccination with live vaccine within 28 days prior to randomization.\nHistory of stroke or intracranial hemorrhage within 6 months of enrollment.\nHistory of allogeneic or autologous stem cell transplant within 60 days of enrollment, presence of either of the following regardless of prior stem cell transplant timing: active graft vs. host disease; cytopenias from incomplete blood cell count recovery post-transplant.\nActive uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.",
        "keywords": []
    },
    {
        "trial_id": "NCT06719128",
        "brief_title": "A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants",
        "official_title": "An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants",
        "lillyAlias": [
            "J3M-OX-JZQF"
        ],
        "brief_summary": "The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Hepatic Insufficiency",
            "Healthy"
        ],
        "drugs_list": [
            "Olomorasib"
        ],
        "enrollment": 48,
        "inclusion_criteria": "inclusion criteria: \n\n Males and females of non-childbearing potential.\n Men or women with a body mass index of 18.0 to 40.0 kilograms per meter squared (kg/m\u00b2).\n Able to comply with all study procedures, including the 5- to 6-night stays at the CRU and the follow-up phone call.\n Healthy participants: In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, or clinical laboratory evaluations at screening and/or admission as assessed by the investigator (or designee).\n Participants with hepatic impairment: Diagnosis of cirrhosis due to parenchymal liver disease, which is confirmed and documented by at least one of the following: medical history, physical examination, hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging, and/or liver biopsy.",
        "exclusion_criteria": "exclusion criteria: \n\nFemales who are lactating or of childbearing potential.\nHistory or presence of any of the following, deemed clinically significant by the Investigator (or designee), and/or Sponsor:\n\n  1. Metabolic disease\n  2. Gastrointestinal disease\n  3. Hematological disease\n  4. Neurological disease\n  5. History or presence of clinically significant cardiovascular disease.\nAbnormal laboratory values determined to be clinically significant by the Investigator (or designee).\nClinically significant abnormality, as determined by the Investigator (or designee), from physical examination.\nParticipation in any other investigational study drug trial involving administration of any investigational drug in the past 30 days or 5 half-lives, whichever was longer, prior to the first dose administration (Day 1).\nUse or intention to use any prescription or over-the-counter medications within 14 days prior to the first dose administration (Day 1) and through end of trial, unless deemed acceptable by the investigator (or designee) and medical monitor.\nHistory or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results, or put the participant at undue risk.",
        "keywords": [
            "Olomorasib",
            "Hepatic Impairment"
        ]
    },
    {
        "trial_id": "NCT04662255",
        "brief_title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)",
        "official_title": "A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Na\u00efve Mantle Cell Lymphoma (BRUIN MCL-321)",
        "lillyAlias": [
            "J2N-OX-JZNM"
        ],
        "brief_summary": "This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Lymphoma, Mantle-Cell"
        ],
        "drugs_list": [
            "Pirtobrutinib",
            "Ibrutinib",
            "Acalabrutinib",
            "Zanubrutinib"
        ],
        "enrollment": 500,
        "inclusion_criteria": "inclusion criteria: \n\n Confirmed MCL diagnosis\n Previously treated with at least one prior line of systemic therapy for MCL\n Measurable disease per Lugano criteria\n Eastern Cooperative Oncology Group (ECOG) 0-2\n Absolute neutrophil count \u2265 0.75 \u00d7 109/L without granulocyte-colony stimulating factor support within 7 days of screening\n Hemoglobin \u2265 8 g/dL not requiring transfusion support or growth factors within 7 days of screening\n Platelets \u2265 50 \u00d7 109/L not requiring transfusion support or growth factors within 7 days of screening.\n AST and ALT \u2264 3.0 x upper limit of normal (ULN)\n Total bilirubin \u2264 1.5 x ULN.\n Creatinine clearance of \u2265 30 mL/min according to Cockcroft/Gault Formula",
        "exclusion_criteria": "exclusion criteria: \n\nPrior treatment with an approved or investigational BTK inhibitor\nHistory of bleeding diathesis\nHistory of stroke or intracranial hemorrhage within 6 months of randomization\nHistory of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor modified T-cell (CAR-T) therapy within 60 days of randomization\nClinically significant cardiovascular disease\nProlonged QT interval corrected using Fridericia's formula (QTcF) \\> 470 ms on 2/3 consecutive ECGs, and mean QTcF\\>470 ms on all 3 ECGs\nKnown HIV infection or active HBV, HCV, or CMV infections. (Certain participants with controlled HBV infections may still be eligible)\nClinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption\nOngoing chronic treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment.\nPatients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.\nVaccination with live vaccine within 28 days prior to randomization",
        "keywords": [
            "Bruton's Tyrosine Kinase Inhibitor",
            "BTKi",
            "Hematologic Disease",
            "Lymphoma, non-Hodgkin's",
            "Lymphoma, B-Cell",
            "Lymphoma",
            "pirtobrutinib"
        ]
    },
    {
        "trial_id": "NCT06643728",
        "brief_title": "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight",
        "official_title": "A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes",
        "lillyAlias": [
            "J4Z-MC-GIDF"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Obesity",
            "Overweight"
        ],
        "drugs_list": [
            "Bimagrumab",
            "Tirzepatide",
            "Bimagrumab Placebo",
            "Tirzepatide Placebo"
        ],
        "enrollment": 240,
        "inclusion_criteria": "inclusion criteria: \n\n Have a BMI of\n\n   \u226530 kilograms per square meter (kg/m2) or\n   \u226527 kg/m2 and \\<30 kg/m2, with at least one of the following weight-related comorbidities:\n\n     Hypertension\n     Dyslipidemia\n     Cardiovascular disease\n     Obstructive sleep apnea\n Have had a stable body weight for the 3 months prior to randomization (\\<5% body weight gain and/or loss)",
        "exclusion_criteria": "exclusion criteria: \n\nHave a prior or planned surgical treatment for obesity\nHave at least one laboratory value suggestive of diabetes during screening\nUse of metformin, or any other glucose-lowering medications\nHave Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma\nHave poorly controlled hypertension\nHave any of the following cardiovascular conditions within 3 months prior to screening:\n\n  acute myocardial infarction\n  cerebrovascular accident (stroke)\n  unstable angina, or\n  hospitalization due to congestive heart failure\nHave ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes\nHave ongoing or a history of bradyarrhythmias other than sinus bradycardia\nHave a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure\nHave a history of symptomatic gallbladder disease within the past 2 years\nHave signs and symptoms of any liver disease\nHave a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality\nHave a history of acute or chronic pancreatitis\nHave renal impairment, measured as estimated glomerular filtration rate \\<30 mL/minute/1.73 m2\nCurrently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening",
        "keywords": [
            "Muscle",
            "Lean",
            "Fat"
        ]
    },
    {
        "trial_id": "NCT06890611",
        "brief_title": "A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants",
        "official_title": "A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants",
        "lillyAlias": [
            "J4Z-MC-GIDG"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Healthy"
        ],
        "drugs_list": [
            "Bimagrumab",
            "Tirzepatide",
            "Bimagrumab + Tirzepatide Coformulation"
        ],
        "enrollment": 100,
        "inclusion_criteria": "inclusion criteria: \n\n Are considered healthy as determined by medical evaluation including medical history and physical examination\n Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive",
        "exclusion_criteria": "exclusion criteria: \n\nHave current or a history of pancreatitis or hepatitis\nHave a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening\nHave uncontrolled high blood pressure\nHave taken medications or alternative remedies to promote weight loss within 3 months prior to screening",
        "keywords": []
    },
    {
        "trial_id": "NCT06602219",
        "brief_title": "A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis",
        "official_title": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants With Moderate-to Severe Plaque Psoriasis",
        "lillyAlias": [
            "J5C-MC-FOAB"
        ],
        "brief_summary": "The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Plaque Psoriasis"
        ],
        "drugs_list": [
            "LY4100511",
            "Placebo"
        ],
        "enrollment": 220,
        "inclusion_criteria": "inclusion criteria: \n\n Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization\n Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).\n Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.\n Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study",
        "exclusion_criteria": "exclusion criteria: \n\nHave had a clinically significant flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator.\nHave a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.\nHave any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.\nHave a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics).\nHave a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.",
        "keywords": []
    },
    {
        "trial_id": "NCT04616326",
        "brief_title": "A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine",
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study",
        "lillyAlias": [
            "I5Q-MC-CGAT"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Chronic Migraine"
        ],
        "drugs_list": [
            "Galcanezumab",
            "Placebo"
        ],
        "enrollment": 300,
        "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of chronic migraine as defined by the IHS ICHD-3 guidelines (1.3 according to ICHD-3 \\[2018\\]), that is, a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month.",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants who are taking, or are expected to take, therapeutic antibodies during the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.). Prior use of therapeutic antibodies is allowed if that use was more than 12 months prior to baseline, except for antibodies to CGRP or its receptor, which are not allowed at any time prior to study entry.\nKnown hypersensitivity monoclonal antibodies or other therapeutic proteins, or to galcanezumab or its excipients.\nCurrent use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor antibody, including those who have previously completed or withdrawn from this study or any other study investigating a CGRP antibody. Participant must also not have prior oral CGRP antagonist use within 30 days prior to baseline.\nHistory of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine and migraine with brainstem aura (previously basilar-type migraine).\nHistory of significant head or neck injury within 6 months prior to screening; or traumatic head injury at any time that is associated with significant change in the quality or frequency of their headaches, including new onset of migraine following traumatic head injury.\nParticipants with a known history of intracranial tumors or developmental malformations including Chiari malformations.",
        "keywords": [
            "pediatric",
            "children",
            "prevention",
            "prophylaxis",
            "headache",
            "pediatric migraine"
        ]
    },
    {
        "trial_id": "NCT06297590",
        "brief_title": "A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease",
        "official_title": "A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer's Disease",
        "lillyAlias": [
            "J4T-MC-OLAA"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.\n\nThe study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid.\n\nThe study will last up to approximately 45 weeks for Part A, and, if conducted, 73 weeks for Part B, including the screening period.\n\nIf the optional bridging period is conducted, participants in Part A could be enrolled in the separate potential study for up to approximately 96 weeks, including the screening period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Alzheimer Disease"
        ],
        "drugs_list": [
            "LY3954068",
            "Placebo",
            "Flortaucipir F18"
        ],
        "enrollment": 32,
        "inclusion_criteria": "inclusion criteria: \n\n Have a body mass index (BMI) within the range 18 (17 for Japan participants) to 40 kilograms per square meter (kg/m\u00b2), inclusive, at screening.\n Have gradual and progressive change in memory function for greater than or equal to (\u2265) 6 months as reported by the participant or informant.\n Have a mini mental state examination (MMSE) score of 18 to 30 at screening.\n Have a clinical dementia rating (CDR) global score of 0.5 to 1.0, with a memory box score \u2265 0.5 at screening.\n Meet flortaucipir F18 positron emission tomography (PET) criteria, as defined in the TAUVID\u2122 FDA label (TAUVID\u2122 prescribing information, 2024), demonstrating evidence of tau pathology.\n Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP).\n Participants must have up to 2 study partners who are with contact with the participant at least 10 hours per week and one of whom can attend study appointments.",
        "exclusion_criteria": "exclusion criteria: \n\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than Alzheimer's Disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than (\\<)24 months.\nHave a sensitivity to flortaucipir F18.\nHave contraindication to magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\nHave a current exposure to an amyloid targeted therapy (ATT). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.\nHave previous exposure to any Investigational Medicinal Product administered intrathecal (IT) or previous exposure to any anti-tau therapy.\nHave a history of clinically significant back pain, back pathology and/or back injury (for example, degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulty with lumbar puncture.",
        "keywords": [
            "Dementia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Tauopathies",
            "Tau",
            "Neurodegenerative Diseases",
            "Neurocognitive Disorders",
            "Mental Disorders",
            "Mild Cognitive Impairment"
        ]
    },
    {
        "trial_id": "NCT06362265",
        "brief_title": "A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus",
        "official_title": "A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus",
        "lillyAlias": [
            "I8H-MC-BDDB"
        ],
        "brief_summary": "The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Type 2 Diabetes Mellitus"
        ],
        "drugs_list": [
            "LY3209590"
        ],
        "enrollment": 22,
        "inclusion_criteria": "inclusion criteria: \n\n Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months\n Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening\n Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m\u00b2)\n Participants are insulin na\u00efve or have been without insulin treatment for at least 3 months prior to screening",
        "exclusion_criteria": "exclusion criteria: \n\nHave had a severe hypoglycemia in the past 6 months\nHave a history of renal impairment\nHave had a blood transfusion or severe blood loss within last 90 days\nHave had a significant weight gain or loss of approximately 6% or more within 3 months prior to screening.\nHave a history of an active or untreated malignancy\nAre receiving or received systemic glucocorticoid therapy\nAre currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product",
        "keywords": [
            "Insulin"
        ]
    },
    {
        "trial_id": "NCT05559359",
        "brief_title": "A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis",
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis",
        "lillyAlias": [
            "J2T-MC-KGBI"
        ],
        "brief_summary": "The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \\<18 years of age with moderate-to-severe atopic dermatitis (AD).",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Atopic Dermatitis",
            "Eczema"
        ],
        "drugs_list": [
            "Lebrikizumab",
            "Placebo",
            "Topical Corticosteroid (TCS)"
        ],
        "enrollment": 360,
        "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of AD prior to screening as stated in the criteria by the American Academy of Dermatology for at least,\n\n   12 months if participants are \u22656 years of age\n   6 months if participants are 2 to \\<6 years of age\n   3 months if participants are 6 months to \\<2 years of age.\n Have an EASI score \u226516 at the screening and baseline\n Have an IGA score \u22653 (scale of 0 to 4) at the screening and baseline\n Have \u226510% BSA of AD involvement at the screening and baseline.",
        "exclusion_criteria": "exclusion criteria: \n\nAre currently enrolled or have participated within the last 8 weeks in a clinical study involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.\nTreatment with the following prior to the baseline:\nAn investigational drug within 8 weeks or less than 5 half-lives, whichever is longer.\nDupilumab within 8 weeks. Note: The enrollment of participants with prior use of Dupilumab will be limited to \\<20%.\nTreatment with a topical investigational drug within 2 weeks prior to the baseline.\nHave received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 weeks before randomization.",
        "keywords": []
    },
    {
        "trial_id": "NCT03432286",
        "brief_title": "A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine",
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study",
        "lillyAlias": [
            "I5Q-MC-CGAS"
        ],
        "brief_summary": "The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Episodic Migraine"
        ],
        "drugs_list": [
            "Galcanezumab",
            "Placebo"
        ],
        "enrollment": 325,
        "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of migraine with or without aura as defined by the IHS ICHD-3 guidelines (1.1 or 1.2 according to ICHD-3 \\[2018\\]), with a history of migraine headaches of at least 6 months prior to screening.",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants who are taking, or are expected to take, therapeutic antibodies during the course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.). Prior use of therapeutic antibodies is allowed if that use was more than 12 months prior to baseline.\nKnown hypersensitivity to monoclonal antibodies or other therapeutic proteins, or to galcanezumab or its excipients.\nCurrent use or prior exposure to galcanezumab, another CGRP antibody, or CGRP receptor antibody, including those who have previously completed or withdrawn from this study or any other study investigating a CGRP antibody.\nHistory of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine and migraine with brainstem aura (previously basilar-type migraine).\nHistory of significant head or neck injury within 6 months prior to screening; or traumatic head injury at any time that is associated with significant change in the quality or frequency of their headaches, including new onset of migraine following traumatic head injury.\nParticipants with a known history of intracranial tumors or developmental malformations including Chiari malformations.",
        "keywords": [
            "pediatric",
            "children",
            "prevention",
            "prophylaxis",
            "headache",
            "pediatric migraine"
        ]
    },
    {
        "trial_id": "NCT05026866",
        "brief_title": "A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)",
        "official_title": "A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease",
        "lillyAlias": [
            "I5T-MC-AACM"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Alzheimer Disease"
        ],
        "drugs_list": [
            "Donanemab",
            "Placebo"
        ],
        "enrollment": 2196,
        "inclusion_criteria": "inclusion criteria: \n\n A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.\n Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid and early-tau pathology.\n Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n Have adequate literacy, vision, and hearing for neuropsychological testing at screening.\n Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.",
        "exclusion_criteria": "exclusion criteria: \n\nMild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.\nCurrent serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately \u22645 years.\nHistory of cancer with high risk of recurrence and preventing completion of the trial.\nHistory of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).\nHave any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.\nHave any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\nHave a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), \\>4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening.\nHave had prior treatment with a passive anti-amyloid immunotherapy \\<5 half-lives prior to randomization.\nHave received active immunization against amyloid beta (A\u03b2) in any other study.\nHave received active immunization against A\u03b2 in any other study.\nCurrent or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.\n\nAddendum 7 Exclusion Criteria for Clinicaltrials.gov:\n\nSame as the main study except contraindications for florbetapir F 18 PET are exclusionary.",
        "keywords": []
    },
    {
        "trial_id": "NCT04396574",
        "brief_title": "A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine",
        "official_title": "A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2",
        "lillyAlias": [
            "H8H-MC-LAHW"
        ],
        "brief_summary": "The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Migraine"
        ],
        "drugs_list": [
            "Lasmiditan"
        ],
        "enrollment": 1000,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have completed study H8H-MC-LAHX (NCT03988088) or study H8H-MC-LAHV (NCT number to be determined)\n Participants must weigh at least 15 kilograms (kg)",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not be pregnant or nursing\nParticipants must not have any acute, serious, or unstable medical condition\nParticipants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator",
        "keywords": [
            "acute",
            "long-term",
            "open label",
            "safety"
        ]
    },
    {
        "trial_id": "NCT06383390",
        "brief_title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)",
        "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index \u226527 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease",
        "lillyAlias": [
            "J1I-MC-GZBO"
        ],
        "brief_summary": "The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Atherosclerotic Cardiovascular Disease (ASCVD)",
            "Chronic Kidney Disease (CKD)"
        ],
        "drugs_list": [
            "Retatrutide",
            "Placebo"
        ],
        "enrollment": 10000,
        "inclusion_criteria": "inclusion criteria: \n\n Participants may be without type 2 diabetes (T2D), or with T2D if their hemoglobin A1c (HbA1c) is 10% or lower\n Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:\n\n   Coronary artery disease\n   Cerebrovascular disease\n   Peripheral arterial disease\n   Chronic kidney disease defined as:\n\n     eGFR \\<45 millilitres/minute/1.73 meter squared (mL/min/1.73m\\^2) and UACR \\>30 milligram/gram (mg/g) (0.030 mg/mg)\n     eGFR \\<60 mL/min/1.73 m\\^2 and UACR \\>100 mg/g (0.100 mg/mg), or\n     eGFR \\<75 mL/min/1.73 m\\^2 and UACR \\>300 mg/g (0.300 mg/mg) (eGFR is calculated by central lab based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin c equation as determined by central lab)\n A Body Mass Index of \u226527.0 kilograms per meter squared (kg/m\\^2)",
        "exclusion_criteria": "exclusion criteria: \n\nDiabetes related:\n\nParticipants have Type 1 Diabetes or any history of diabetic ketoacidosis\n\nCV related:\n\nParticipants have any of the following cardiovascular conditions \u2264 90 days prior to randomization:\n\n  Myocardial infarction\n  Acute coronary syndrome\n  Stroke, or\n  Coronary, peripheral, or carotid artery arterial revascularization procedure.\nHave acute decompensated heart failure requiring hospitalization.\nHave New York Heart Association (NYHA) Classification Class IV heart failure at screening\n\nKidney related:\n\nParticipants have an eGFR \\<20 mL/min/1.73 m\\^2 at screening\nHave UACR \\>5000 mg/g (5.000 mg/mg) at screening\nHave received any form of dialysis \u2264 90 days from the date of randomization\nHave either undergone a kidney transplant or have a transplant procedure scheduled\n\nOther medical conditions:\n\nParticipants have had or plan to have a surgical treatment for obesity,\nHave a history of chronic or acute pancreatitis\nHave a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2\nHave a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction",
        "keywords": [
            "Cardiovascular Disease",
            "Kidney Disease",
            "Major Adverse Cardiovascular Events (MACE)",
            "Renal Outcomes",
            "Cardiovascular Risk Reduction",
            "Kidney Disease Progression",
            "Cardiometabolic Risk Factors",
            "Cardiovascular Outcomes",
            "Kidney Outcomes",
            "Type 2 Diabetes",
            "Heart Disease",
            "Coronary Artery Disease",
            "Cerebrovascular Disease",
            "Peripheral Arterial Disease",
            "Nonfatal Myocardial Infarction (MI)",
            "Nonfatal Stroke",
            "Cardiovascular (CV) Death",
            "Hospitalization or Urgent Visit Due to Heart Failure (HF)",
            "Renal Death",
            "End Stage Kidney Disease (ESKD)"
        ]
    }
]